{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:16:58Z","timestamp":1700353018679},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Riphah International University, Islamabad"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The purpose of the study was to compare results and evaluate the agreement between the endpoint fluorescence (EPF) method and quantitative real-time polymerase chain reaction (QPCR) during molecular monitoring of patients with chronic myeloid leukemia (CML) receiving treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>The study was conducted at Molecular Lab of Riphah International University, Islamabad, Pakistan, from January 2017 to December 2018. A total of 150 blood specimens from 30 patients with CML were analyzed at regular intervals during therapy. The detection\/quantification of transcript mRNA was done simultaneously using QPCR and the EPF method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Out of a total of 150 RNA specimens analyzed, 117 (78%) specimens were positive, whereas 33 (22%) were negative for the transcript using both methods at various stages of treatment. Strong linear negative correlations between the cycle threshold and relative fluorescence unit values were observed with P\u2005&amp;lt;.0001 at 0, 3, 6, 9, and 12 months of treatment. No significant difference (P\u2005&amp;gt;.05) between the means of the BCR-ABL percentage was observed in either method at all stages of treatment. The bias between the 2 methods was calculated as 0.069 \u00b1 3.50, and 95% limits of agreement were 6.92% to \u20136.79%.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We found that EPF is s simple method to detect\/quantify BCR-ABL mRNA expression during treatment with comparable results to QPCR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmab075","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T19:09:10Z","timestamp":1628449750000},"page":"183-189","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Monitoring of <i>BCR-ABL<\/i> Fusion Transcripts in Patients with Chronic Myeloid Leukemia During Treatment Using the Endpoint Fluorescence Method"],"prefix":"10.1093","volume":"53","author":[{"given":"Huma","family":"Amin","sequence":"first","affiliation":[{"name":"Department of Pathology, Rawalpindi Medical University , Rawalpindi , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suhaib","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Islamic International Medical College, Rawalpindi, Pakistan, and Riphah International University , Islamabad , Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"issue":"2","key":"2023111812345094600_CIT0001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol."},{"issue":"5","key":"2023111812345094600_CIT0002","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","article-title":"Best practices in chronic myeloid leukemia monitoring and management","volume":"21","author":"Soverini","year":"2016","journal-title":"Oncologist."},{"key":"2023111812345094600_CIT0003","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/asheducation.V2012.1.105.3798223","article-title":"Monitoring after successful therapy for chronic myeloid leukemia","volume":"2012","author":"Branford","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"4","key":"2023111812345094600_CIT0004","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood."},{"issue":"6","key":"2023111812345094600_CIT0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood."},{"issue":"1","key":"2023111812345094600_CIT0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1525-1578(10)60675-7","article-title":"Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring","volume":"4","author":"Bagg","year":"2002","journal-title":"J Mol Diagn."},{"issue":"4","key":"2023111812345094600_CIT0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4172\/2161-0681.1000113","article-title":"Molecular monitoring and treatment of chronic myeloid leukemia (CML)","volume":"2","author":"Singh","year":"2012","journal-title":"J Clin Exp Pathol."},{"issue":"1","key":"2023111812345094600_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3329\/bmrcb.v34i1.1162","article-title":"Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh","volume":"34","author":"Sultana","year":"2008","journal-title":"Bangladesh Med Res Counc Bull."},{"issue":"2","key":"2023111812345094600_CIT0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/ajts.AJTS_90_19","article-title":"Comparison of UV spectrometry and fluorometry-based methods for quantification of cell-free DNA in red cell components","volume":"13","author":"Khetan","year":"2019","journal-title":"Asian J Transfus Sci."},{"issue":"1","key":"2023111812345094600_CIT0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12936-018-2191-y","article-title":"Detection of asymptomatic carriers of malaria in Kohat district of Pakistan","volume":"17","author":"Naeem","year":"2018","journal-title":"Malar J."},{"issue":"5","key":"2023111812345094600_CIT0011","first-page":"18","article-title":"Applications of fluorescence spectroscopy","author":"Naresh","year":"2014","journal-title":"J Chem Pharm Sci."},{"issue":"3","key":"2023111812345094600_CIT0012","first-page":"190","article-title":"Real time polymerase chain reaction in diagnosis of chronic myeloid leukemia","volume":"24","author":"Tashfeen","year":"2014","journal-title":"J Coll Physicians Surg Pak."},{"issue":"3","key":"2023111812345094600_CIT0013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4314\/tjpr.v16i3.22","article-title":"Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response","volume":"16","author":"Ting","year":"2017","journal-title":"Trop J Pharm Res."},{"issue":"Supplement","key":"2023111812345094600_CIT0014","first-page":"136","article-title":"Dual transcripts of BCR-ABL and different polymorphisms in chronic myeloid leukaemia patients","volume":"143","author":"Nandagopalan","year":"2016","journal-title":"Indian J Med Res."},{"issue":"6","key":"2023111812345094600_CIT0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.leu.2401426","article-title":"Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a \u201creal time\u201d quantitative RT-PCR assay","volume":"13","author":"Preudhomme","year":"1999","journal-title":"Leukemia."},{"key":"2023111812345094600_CIT0016","first-page":"138","article-title":"Molecular monitoring of BCR-ABL transcripts standardization needed to properly use, and further investigate the value of, a critical surrogate marker for success in therapy of chronic myeloid leukemia","volume":"7","author":"Giles","year":"2011","journal-title":"US Oncol Hematol."},{"issue":"2","key":"2023111812345094600_CIT0017","first-page":"107","article-title":"Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib","volume":"45","author":"Ashariati","year":"2013","journal-title":"Acta Med Indones."},{"issue":"16","key":"2023111812345094600_CIT0018","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood."},{"issue":"7","key":"2023111812345094600_CIT0019","first-page":"593","article-title":"Detection of BCR-ABL transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis","volume":"83","author":"Martinelli","year":"1998","journal-title":"Haematologica."},{"issue":"1","key":"2023111812345094600_CIT0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JGO.2015.002667","article-title":"Chronic myeloid leukemia in India","volume":"3","author":"Ganesan","year":"2017","journal-title":"J Glob Oncol."},{"issue":"Supplement 4","key":"2023111812345094600_CIT0021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2017","journal-title":"Ann Oncol."},{"issue":"3","key":"2023111812345094600_CIT0022","first-page":"252","article-title":"Real-time quantification of different types of BCR-ABL transcript in chronic myeloid leukemia","volume":"86","author":"Amabile","year":"2001","journal-title":"Haematologica."},{"issue":"5","key":"2023111812345094600_CIT0023","doi-asserted-by":"crossref","first-page":"BSR20180974","DOI":"10.1042\/BSR20180974","article-title":"Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for \u201cminimal residual disease\u201d assessment in chronic myeloid leukemia","volume":"38","author":"Azad","year":"2018","journal-title":"Biosci Rep."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/2\/183\/53511895\/lmab075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/53\/2\/183\/53511895\/lmab075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:35:10Z","timestamp":1700310910000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/53\/2\/183\/6370398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,9,15]]},"published-print":{"date-parts":[[2022,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmab075","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,9,15]]}}}